Sharma V, Bagrodia V, Kulshreshtra A. Enhancing hemophilia A management: emicizumab as a cost-effective adjunct to standard therapy for inhibitor patients. Int J Basic Clin Pharmacol [Internet]. 2024 Apr. 25 [cited 2025 Oct. 23];13(3):395-7. Available from: https://www.ijbcp.com/index.php/ijbcp/article/view/5579